SUVEN LIFE SCIENCES LTD
SUVEN · Pharma · NSE
₹269
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SUVEN yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
3/9
Economic Moat
None
Confidence
8%
ROE
-78.8%
Debt/Equity
0.03
WACC
9.7%
Market Cap
₹7,089 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-140.8%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-3214.0×
EBIT covers interest
Current Ratio
3.21×
Short-term liquidity
Asset Turnover
0.05×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-19.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
SUVEN · last 8 annual periods
ROE
-9.8%
ROCE
-140.8%
Operating Margin
—
Debt / Equity
—
PE
—
EV / EBITDA
—
Historical Financials
SUVEN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹11.8 Cr | — | — | — | — | +0.0% |
| EBITDA | ₹-117 Cr | ₹-111 Cr | ₹-99.4 Cr | ₹-155 Cr | ₹-271 Cr | — |
| EBIT | ₹-121 Cr | ₹-118 Cr | ₹-106 Cr | — | — | — |
| PAT | ₹-122 Cr | ₹-118 Cr | ₹-105 Cr | ₹-161 Cr | ₹-276 Cr | — |
| EPS (diluted) | ₹-9.57 | ₹-6.63 | ₹-4.82 | — | — | — |
| CFO | ₹-128 Cr | ₹-116 Cr | ₹-82.6 Cr | ₹-154 Cr | ₹-302 Cr | — |
| CapEx | ₹-19.8 Cr | ₹-2.9 Cr | — | ₹-37.3 Cr | ₹-5.1 Cr | — |
| FCF | ₹-147 Cr | ₹-119 Cr | — | ₹-191 Cr | ₹-307 Cr | — |
| Total Assets | ₹108 Cr | ₹389 Cr | ₹285 Cr | ₹135 Cr | ₹624 Cr | +55.0% |
| Total Debt | ₹3.2 Cr | ₹1.6 Cr | ₹0.7 Cr | ₹0.0 Cr | ₹16.7 Cr | +51.0% |
| Shareholders' Equity | ₹96.1 Cr | ₹375 Cr | ₹270 Cr | ₹110 Cr | ₹591 Cr | +57.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SUVEN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 FDC FDC | — | — | Pending | 11.3% | 18.6× |
AARTIPHARM AARTIPHARM | — | — | Pending | 8.2% | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
 SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
PGHL PGHL | — | — | Pending | 3.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
3 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
—
Last payout
2019-02-14
₹1.38
Peak payout
₹1.38
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of SUVEN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SUVEN →
Compare
Head-to-head with peers
Compare SUVEN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SUVENNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.